Anaplastic Astrocytoma Therapeutic Products and Pipeline Assessment Review H1 2015 Market Research Report Available at RnRMarketResearch.com
Dallas, TX (PRWEB) June 19, 2015 -- The report “Anaplastic Astrocytoma - Pipeline Review, H1 2015” provides comprehensive information on the therapeutic development for Anaplastic Astrocytoma. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report on Anaplastic Astrocytoma with 33 market data tables and 14 figures, spread across 108 pages is available at http://www.rnrmarketresearch.com/anaplastic-astrocytoma-pipeline-review-h1-2015-market-report.html .
Companies discussed in this Anaplastic Astrocytoma - Pipeline Review, H1 2015 report include Amgen Inc., Boehringer Ingelheim GmbH, Burzynski Research Institute, Inc., Cavion LLC, e-Therapeutics plc, Eli Lilly and Company, Millennium Pharmaceuticals, Inc., Novartis AG, Oncovir, Inc., Orbus Therapeutics, Inc., Pfizer Inc., Sanofi, Tocagen Inc., TVAX Biomedical, Inc.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Drug Profiles mentioned in this report are afatinib, alisertib, AMG-595, Antineoplaston Therapy, Dendritic Cell Therapy for Gliomas, Dendritic Cell Therapy for Oncology, DNX-2401, eflornithine hydrochloride, ETS-2101, galunisertib, mibefradil dihydrochloride, Oncolytic Virus to Target IL-12 for Oncology, panobinostat, plerixafor, Poly-ICLC, Stem Cell Therapy for Glioma, temsirolimus, TVI-Brain-1, vocimagene amiretrorepvec + flucytosine ER.
Order a purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=392674 . (This is a premium report priced at US$2000 for a single user License.)
List of Tables
Number of Products under Development for Anaplastic Astrocytoma, H1 2015 9
Number of Products under Development for Anaplastic Astrocytoma - Comparative Analysis, H1 2015 10
Number of Products under Development by Companies, H1 2015 11
Number of Products under Investigation by Universities/Institutes, H1 2015 12
Comparative Analysis by Late Stage Development, H1 2015 13
Comparative Analysis by Clinical Stage Development, H1 2015 14
Products under Development by Companies, H1 2015 15
Products under Development by Companies, H1 2015 (Contd..1) 16
Products under Investigation by Universities/Institutes, H1 2015 17
Anaplastic Astrocytoma - Pipeline by Amgen Inc., H1 2015 18
Anaplastic Astrocytoma - Pipeline by Boehringer Ingelheim GmbH, H1 2015 19
Anaplastic Astrocytoma - Pipeline by Burzynski Research Institute, Inc., H1 2015 20
Anaplastic Astrocytoma - Pipeline by Cavion LLC, H1 2015 21
Anaplastic Astrocytoma - Pipeline by e-Therapeutics plc, H1 2015 22
Anaplastic Astrocytoma - Pipeline by Eli Lilly and Company, H1 2015 23
Anaplastic Astrocytoma - Pipeline by Millennium Pharmaceuticals, Inc., H1 2015 24
Anaplastic Astrocytoma - Pipeline by Novartis AG, H1 2015 25
Anaplastic Astrocytoma - Pipeline by Oncovir, Inc., H1 2015 26
Anaplastic Astrocytoma - Pipeline by Orbus Therapeutics, Inc., H1 2015 27
Anaplastic Astrocytoma - Pipeline by Pfizer Inc., H1 2015 28
Anaplastic Astrocytoma - Pipeline by Sanofi, H1 2015 29
Anaplastic Astrocytoma - Pipeline by Tocagen Inc., H1 2015 30
Anaplastic Astrocytoma - Pipeline by TVAX Biomedical, Inc., H1 2015 31
Assessment by Monotherapy Products, H1 2015 32
Assessment by Combination Products, H1 2015 33
Number of Products by Stage and Target, H1 2015 36
Number of Products by Stage and Mechanism of Action, H1 2015 38
Number of Products by Stage and Route of Administration, H1 2015 40
Number of Products by Stage and Molecule Type, H1 2015 42
Anaplastic Astrocytoma Therapeutics - Recent Pipeline Updates, H1 2015 85
Anaplastic Astrocytoma - Dormant Projects, H1 2015 105
Anaplastic Astrocytoma - Discontinued Products, H1 2015 106
List of Figures
Number of Products under Development for Anaplastic Astrocytoma, H1 2015 9
Number of Products under Development for Anaplastic Astrocytoma - Comparative Analysis, H1 2015 10
Number of Products under Development by Companies, H1 2015 11
Number of Products under Investigation by Universities/Institutes, H1 2015 12
Comparative Analysis by Clinical Stage Development, H1 2015 14
Assessment by Monotherapy Products, H1 2015 32
Number of Products by Top 10 Targets, H1 2015 34
Number of Products by Stage and Top 10 Targets, H1 2015 35
Number of Products by Top 10 Mechanism of Actions, H1 2015 37
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 37
Number of Products by Top 10 Routes of Administration, H1 2015 39
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 40
Number of Products by Top 10 Molecule Types, H1 2015 41
Number of Products by Stage and Top 10 Molecule Types, H1 2015 42
Explore more reports on cancer therapeutics at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/cancer-therapeutics .
About Us:
RnRMarketResearch.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.
Ritesh Tiwari, RnR Market Research, http://www.rnrmarketresearch.com/, +1 (888) 391-5441, [email protected]
Share this article